Phase II Randomized, Placebo-controlled Trial of Green Tea Extract in Patients with High-risk Oral Premalignant Lesions

Epidemiologic and preclinical data support the oral-cancer prevention potential of green tea extract (GTE). We randomly assigned patients with high-risk oral premalignant lesions (OPLs) to receive GTE at 500 mg/m(2), 750 mg/m(2), or 1000 mg/m(2) or placebo TID for 12 weeks, evaluating biomarkers in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Prev Res (Phila)
Autores principales: Tsao, Anne S., Liu, Diane, Martin, Jack, Tang, Xi-ming, Lee, J. Jack, El-Naggar, Adel K., Wistuba, Ignacio, Culotta, Kirk S., Mao, Li, Gillenwater, Ann, Sagesaka, Yuko M., Hong, Waun K., Papadimitrakopoulou, Vassiliki
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4243312/
https://ncbi.nlm.nih.gov/pubmed/19892663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-09-0121
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares